Total Payments
$477,895
2024 Payments
$55,304
Companies
19
Transactions
452
Medicare Patients
5,582
Medicare Billing
$372,715
Payment Breakdown by Category
Other$286,208 (59.9%)
Consulting$130,842 (27.4%)
Travel$51,377 (10.8%)
Food & Beverage$9,423 (2.0%)
Education$45.00 (0.0%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $286,208 | 80 | 59.9% |
| Consulting Fee | $130,842 | 54 | 27.4% |
| Travel and Lodging | $51,377 | 138 | 10.8% |
| Food and Beverage | $9,423 | 172 | 2.0% |
| Education | $45.00 | 8 | 0.0% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, Inc. | $370,333 | 274 | $0 (2024) |
| Medtronic, Inc. | $44,323 | 48 | $0 (2023) |
| Actelion Pharmaceuticals US, Inc. | $13,507 | 29 | $0 (2024) |
| United Therapeutics Corporation | $11,323 | 46 | $0 (2024) |
| PFIZER INC. | $10,518 | 10 | $0 (2024) |
| Regeneron Pharmaceuticals, Inc. | $9,569 | 14 | $0 (2019) |
| AGEPHA Pharma FZ LLC | $6,728 | 4 | $0 (2024) |
| Bayer Healthcare Pharmaceuticals Inc. | $3,832 | 3 | $0 (2024) |
| Cleerly, Inc. | $3,200 | 2 | $0 (2024) |
| E.R. Squibb & Sons, L.L.C. | $2,750 | 4 | $0 (2022) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $55,304 | 57 | Boehringer Ingelheim Pharmaceuticals, Inc. ($22,141) |
| 2023 | $61,910 | 61 | Boehringer Ingelheim Pharmaceuticals, Inc. ($39,458) |
| 2022 | $66,132 | 53 | Boehringer Ingelheim Pharmaceuticals, Inc. ($45,682) |
| 2021 | $79,576 | 62 | Boehringer Ingelheim Pharmaceuticals, Inc. ($67,616) |
| 2020 | $61,124 | 49 | Boehringer Ingelheim Pharmaceuticals, Inc. ($57,149) |
| 2019 | $69,274 | 66 | Boehringer Ingelheim Pharmaceuticals, Inc. ($55,900) |
| 2018 | $49,254 | 61 | Boehringer Ingelheim Pharmaceuticals, Inc. ($47,591) |
| 2017 | $35,320 | 43 | Boehringer Ingelheim Pharmaceuticals, Inc. ($34,797) |
All Payment Transactions
452 individual payment records from CMS Open Payments — Page 1 of 19
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/17/2024 | Actelion Pharmaceuticals US, Inc. | OPSUMIT (Drug) | Consulting Fee | Cash or cash equivalent | $2,725.00 | General |
| Category: Cardiology | ||||||
| 12/10/2024 | Boehringer Ingelheim Pharmaceuticals, Inc. | — | Travel and Lodging | In-kind items and services | $865.57 | General |
| 12/10/2024 | Boehringer Ingelheim Pharmaceuticals, Inc. | — | Travel and Lodging | In-kind items and services | $397.06 | General |
| 12/10/2024 | Boehringer Ingelheim Pharmaceuticals, Inc. | — | Food and Beverage | In-kind items and services | $122.54 | General |
| 12/09/2024 | Boehringer Ingelheim Pharmaceuticals, Inc. | — | Travel and Lodging | In-kind items and services | $163.51 | General |
| 12/09/2024 | Boehringer Ingelheim Pharmaceuticals, Inc. | — | Food and Beverage | In-kind items and services | $94.03 | General |
| 12/04/2024 | Boehringer Ingelheim Pharmaceuticals, Inc. | — | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $3,510.00 | General |
| 12/04/2024 | PFIZER INC. | ELIQUIS (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $1,000.00 | General |
| Category: CARDIOVASCULAR;METABOLIC DISEASE | ||||||
| 12/04/2024 | Actelion Pharmaceuticals US, Inc. | OPSUMIT (Drug) | Travel and Lodging | Cash or cash equivalent | $130.86 | General |
| Category: Cardiology | ||||||
| 12/04/2024 | Actelion Pharmaceuticals US, Inc. | OPSUMIT (Drug) | Food and Beverage | In-kind items and services | $39.44 | General |
| Category: Cardiology | ||||||
| 12/04/2024 | Actelion Pharmaceuticals US, Inc. | OPSUMIT (Drug) | Food and Beverage | Cash or cash equivalent | $26.54 | General |
| Category: Cardiology | ||||||
| 12/04/2024 | Actelion Pharmaceuticals US, Inc. | OPSUMIT (Drug) | Food and Beverage | In-kind items and services | $20.95 | General |
| Category: Cardiology | ||||||
| 12/03/2024 | Actelion Pharmaceuticals US, Inc. | OPSUMIT (Drug) | Travel and Lodging | In-kind items and services | $528.81 | General |
| Category: Cardiology | ||||||
| 12/03/2024 | Actelion Pharmaceuticals US, Inc. | OPSUMIT (Drug) | Travel and Lodging | In-kind items and services | $324.90 | General |
| Category: Cardiology | ||||||
| 11/30/2024 | AGEPHA Pharma FZ LLC | LODOCO (Drug) | Consulting Fee | Cash or cash equivalent | $4,500.00 | General |
| Category: Cardiovascular Diseases | ||||||
| 11/26/2024 | United Therapeutics Corporation | — | Consulting Fee | Cash or cash equivalent | $6,050.00 | General |
| 11/15/2024 | United Therapeutics Corporation | — | Travel and Lodging | Cash or cash equivalent | $115.46 | General |
| 11/15/2024 | United Therapeutics Corporation | — | Food and Beverage | In-kind items and services | $60.00 | General |
| 11/15/2024 | United Therapeutics Corporation | — | Food and Beverage | In-kind items and services | $50.00 | General |
| 11/15/2024 | United Therapeutics Corporation | — | Food and Beverage | In-kind items and services | $30.99 | General |
| 11/15/2024 | United Therapeutics Corporation | — | Food and Beverage | In-kind items and services | $28.42 | General |
| 11/15/2024 | United Therapeutics Corporation | — | Food and Beverage | In-kind items and services | $23.65 | General |
| 11/15/2024 | United Therapeutics Corporation | — | Travel and Lodging | Cash or cash equivalent | $19.50 | General |
| 11/15/2024 | United Therapeutics Corporation | — | Food and Beverage | In-kind items and services | $18.94 | General |
| 11/15/2024 | United Therapeutics Corporation | — | Travel and Lodging | Cash or cash equivalent | $18.00 | General |
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 12 | 1,338 | 1,663 | $234,727 | $92,890 |
| 2022 | 10 | 1,325 | 1,676 | $244,144 | $97,516 |
| 2021 | 12 | 1,418 | 1,636 | $226,417 | $87,139 |
| 2020 | 13 | 1,501 | 1,880 | $263,913 | $95,171 |
Total Patients
5,582
Total Services
6,855
Medicare Billing
$372,715
Procedure Codes
49
All Medicare Procedures & Services
49 procedure records from CMS Medicare Utilization — Page 2 of 2
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 93306 | Ultrasound examination of heart including color-depicted blood flow rate, direction, and valve function | Facility | 2021 | 349 | 357 | $82,710 | $20,343 | 24.6% |
| 99205 | New patient outpatient visit, total time 60-74 minutes | Facility | 2021 | 66 | 66 | $19,140 | $9,689 | 50.6% |
| 78451 | Nuclear medicine study of vessels of heart using drugs or exercise single study | Facility | 2021 | 53 | 53 | $7,049 | $2,858 | 40.5% |
| 93010 | Routine electrocardiogram (ekg) using at least 12 leads with interpretation and report | Facility | 2021 | 269 | 278 | $10,425 | $1,888 | 18.1% |
| 93016 | Exercise or drug-induced heart and blood vessel stress test with ekg monitoring and physician supervision | Facility | 2021 | 92 | 92 | $5,060 | $1,643 | 32.5% |
| 93018 | Exercise or drug-induced heart and blood vessel stress test with ekg monitoring, physician interpretation and report | Facility | 2021 | 105 | 105 | $5,250 | $1,241 | 23.6% |
| 78452 | Nuclear medicine study of vessels of heart using drugs or exercise multiple studies | Facility | 2021 | 19 | 19 | $3,458 | $1,204 | 34.8% |
| 93227 | Heart rhythm tracing, analysis, and interpretation of 48-hour ekg | Facility | 2021 | 46 | 47 | $3,055 | $721.92 | 23.6% |
| 93350 | Ultrasound examination of the heart performed during rest, exercise, and/or drug-induced stress with interpretation and report | Facility | 2021 | 11 | 11 | $1,980 | $634.15 | 32.0% |
| 93272 | Heart rhythm symptom-related interpretation of 24-hour ekg monitoring up to 30 days | Facility | 2021 | 11 | 11 | $660.00 | $224.73 | 34.1% |
| 93321 | Follow-up or limited heart doppler ultrasound study of heart blood flow, valves, and chambers | Facility | 2021 | 16 | 16 | $480.00 | $94.72 | 19.7% |
| 99214 | Established patient office or other outpatient, visit typically 25 minutes | Facility | 2020 | 419 | 776 | $116,400 | $48,553 | 41.7% |
| 93306 | Ultrasound examination of heart including color-depicted blood flow rate, direction, and valve function | Facility | 2020 | 326 | 337 | $76,890 | $20,216 | 26.3% |
| 99205 | New patient office or other outpatient visit, typically 60 minutes | Facility | 2020 | 85 | 85 | $24,650 | $11,432 | 46.4% |
| 78451 | Nuclear medicine study of vessels of heart using drugs or exercise single study | Facility | 2020 | 65 | 65 | $8,645 | $3,598 | 41.6% |
| 99215 | Established patient office or other outpatient, visit typically 40 minutes | Facility | 2020 | 34 | 34 | $6,970 | $3,149 | 45.2% |
| 93010 | Routine electrocardiogram (ekg) using at least 12 leads with interpretation and report | Facility | 2020 | 234 | 241 | $9,038 | $1,657 | 18.3% |
| 93016 | Exercise or drug-induced heart and blood vessel stress test with ekg monitoring and physician supervision | Facility | 2020 | 90 | 90 | $4,950 | $1,640 | 33.1% |
| 78452 | Nuclear medicine study of vessels of heart using drugs or exercise multiple studies | Facility | 2020 | 25 | 25 | $4,550 | $1,633 | 35.9% |
| 93018 | Exercise or drug-induced heart and blood vessel stress test with ekg monitoring, physician interpretation and report | Facility | 2020 | 126 | 128 | $6,400 | $1,550 | 24.2% |
| 93227 | Heart rhythm tracing, analysis, and interpretation of 48-hour ekg | Facility | 2020 | 50 | 51 | $3,315 | $1,099 | 33.1% |
| 93228 | Heart rhythm tracing, computer analysis, and interpretation of patient-triggered events greater than 24-hour ekg up to 30 days | Facility | 2020 | 19 | 19 | $1,235 | $421.64 | 34.1% |
| 93922 | Ultrasound study of arteries of both arms and legs | Facility | 2020 | 12 | 12 | $360.00 | $125.31 | 34.8% |
| 93321 | Follow-up or limited heart doppler ultrasound study of heart blood flow, valves, and chambers | Facility | 2020 | 16 | 17 | $510.00 | $97.64 | 19.1% |
About Dr. Andrew Freeman, MD
Dr. Andrew Freeman, MD is a Cardiovascular Disease healthcare provider based in Denver, Colorado. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 07/20/2008. The National Provider Identifier (NPI) number assigned to this provider is 1770748782.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Andrew Freeman, MD has received a total of $477,895 in payments from pharmaceutical and medical device companies, with $55,304 received in 2024. These payments were reported across 452 transactions from 19 companies. The most common payment nature is "Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program" ($286,208).
As a Medicare-enrolled provider, Freeman has provided services to 5,582 Medicare beneficiaries, totaling 6,855 services with total Medicare billing of $372,715. Data is available for 4 years (2020–2023), covering 49 distinct procedure/service records.
Ad
Practice Information
- Specialty Cardiovascular Disease
- Location Denver, CO
- Active Since 07/20/2008
- Last Updated 02/22/2021
- Taxonomy Code 207RC0000X
- Entity Type Individual
- NPI Number 1770748782
Products in Payments
- JARDIANCE (Drug) $29,254
- PRALUENT (Biological) $9,569
- OPSUMIT (Drug) $9,173
- LODOCO (Drug) $6,728
- ORENITRAM (Drug) $4,029
- UPTRAVI (Drug) $3,642
- ELIQUIS (Drug) $3,568
- Kerendia (Drug) $3,432
- CAMZYOS (Drug) $2,700
- OPSUMIT MACITENTAN (Drug) $645.18
- Adempas (Drug) $400.00
- WATCHMAN (Device) $117.88
- SQRX PULSE GENERATOR (Device) $111.68
- GENERAL - TACHY (Device) $109.15
- GENERAL - EP HARDWARE (Device) $105.14
- ATRIAL FIBRILLATION - DISEASE (Drug) $100.00
- GENERAL THERAPIES (Device) $77.27
- GENERAL - THERAPIES (Device) $70.01
- Vascepa (Drug) $68.52
- LINQ II (Device) $48.38
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Cardiovascular Disease Doctors in Denver
Matthew Holland, M.d, M.D
Cardiovascular Disease — Payments: $46,811
Cardiovascular Disease $46,811
Dr. Christopher Barrett, M.d, M.D
Cardiovascular Disease — Payments: $33,700
Cardiovascular Disease $33,700
Alexis Tumolo, M.d, M.D
Cardiovascular Disease — Payments: $32,631
Cardiovascular Disease $32,631
Glenn Hirsch, M.d, M.D
Cardiovascular Disease — Payments: $30,595
Cardiovascular Disease $30,595
Dr. Mori Krantz, Md, MD
Cardiovascular Disease — Payments: $22,589
Cardiovascular Disease $22,589
John Rumsfeld, M.d., Ph.d, M.D., PH.D
Cardiovascular Disease — Payments: $22,304
Cardiovascular Disease $22,304